Treatment of Premature Ejaculation (PE) with Comorbid Erectile Dysfunction (ED)

Understanding the Comorbidity

• Campbell Walsh Wein Urology, p. 2080

Management Algorithm

Step 1: Treat the Underlying ED First (When PE is Secondary to ED)

• PDE5 inhibitors (sildenafil, tadalafil, vardenafil) - these address the ED, which in turn reduces performance anxiety and the "rushing" behavior that causes PE
• Even when PE is not purely secondary, PDE5Is still have independent benefit on PE: they reduce performance anxiety, delay the ejaculatory reflex by increasing smooth muscle relaxation and nitric oxide tone, and improve ejaculatory control
• PDE5I drugs show efficacy for PE even in men without objective ED, likely via central and peripheral pathways

Step 2: Pharmacologic Treatment of PE

SSRIs and TCAs (First-Line for PE)

• Campbell Walsh Wein Urology, p. 2083-2086

Combination: SSRI + PDE5 Inhibitor

• Adding a PDE5 inhibitor to an SSRI produces better prolongation of ejaculatory latency than SSRI alone (Goldman-Cecil Medicine)
• The PDE5I treats the underlying ED, reduces performance anxiety, and appears to independently delay ejaculation
• The SSRI (especially dapoxetine) provides direct ejaculatory inhibition
• Multiple studies confirm superior outcomes with combination therapy vs. monotherapy in this population

Topical Local Anesthetics

• Lidocaine/prilocaine cream, gel, or spray (e.g., EMLA cream, lidocaine 2.5% + prilocaine 2.5%)
• Applied to the glans penis 20-30 minutes before intercourse, wiped off before penetration
• Inhibit the spinal reflex arc responsible for ejaculation by reducing glans sensitivity
• Caution: May cause penile hypoanesthesia and can be transferred vaginally causing female partner numbness/anorgasmia unless a condom is used
• Useful alternative when SSRIs are contraindicated or not tolerated
• Campbell Walsh Wein Urology, p. 2086

Tramadol (On-Demand, Off-Label)

• Centrally-acting synthetic opioid analgesic; delays ejaculation via μ-opioid binding and weak SNRI activity
• IELT increase ~2.49x in double-blind trials (inferior to paroxetine: 22x vs 5x for tramadol)
• Reserve as a second-line option given modest efficacy and opioid dependence risk
• Campbell Walsh Wein Urology, p. 2087

Step 3: Psychosexual and Behavioral Therapy

• Behavioral techniques: Stop-start method (Semans), pause-squeeze technique (Masters and Johnson) - teach men to recognize pre-ejaculatory sensations and voluntarily delay
• Cognitive-behavioral therapy (CBT): Addresses performance anxiety, rigid sexual scripts, avoidance behaviors, and partner relationship issues
• Goals include: improving ejaculatory control, reducing anxiety, improving self-confidence, and enhancing couple communication
• Partner involvement is strongly recommended - a cooperative partner enhances confidence, self-esteem, and sense of control

• Campbell Walsh Wein Urology, p. 2085-2086

Step 4: Treat Underlying Causes of Acquired PE

Emerging and Investigational Therapies

• Oxytocin receptor antagonists (e.g., IX-01): Phase IIA trial showed 3.6x IELT increase (vs 1.8x placebo); promising CNS-penetrating agent under development - Goldman-Cecil Medicine, p. 879; Campbell Walsh Wein, p. 2089
• Botulinum toxin-A injection: 2025 meta-analysis (PMID: 40445933) supports efficacy and safety as a PE treatment option
• Modafinil: Preclinical data suggest ejaculation delay via serotonergic/dopaminergic pathways; not yet in routine clinical use

Key Points Summary

1. First, confirm true comorbid ED - rule out false-positive SHIM scores from PE patients
2. If PE is secondary to ED, treat ED first with PDE5Is - PE may resolve
3. SSRI + PDE5 inhibitor combination is the pharmacologic mainstay for true PE + ED comorbidity
4. Dapoxetine is the preferred on-demand SSRI (safe with PDE5Is, effective in this population)
5. Topical anesthetics are useful alternatives when systemic therapy is not preferred
6. Psychosexual therapy must accompany pharmacotherapy - especially in acquired PE with performance anxiety
7. Treat reversible causes (prostatitis, hyperthyroidism) in acquired PE

• Campbell Walsh Wein Urology, pp. 2080-2089
• Goldman-Cecil Medicine, p. 879

Desmopressin Nasal Spray - Indications, Age Groups, Doses & Indian Brands

Formulation

• Concentration: 0.01% w/v (0.1 mg/mL = 10 mcg per 0.1 mL spray)
• Delivery: Each pump spray delivers 10 mcg per actuation
• Pack size: Typically 5 mL bottle = 50 sprays
• Nasal bioavailability: 3-4% (intranasal is ~10-40x more potent than oral tablets)
• Katzung's Basic & Clinical Pharmacology, 16th Ed.

Indications

Dosing by Age Group

1. Central Diabetes Insipidus

The morning and evening doses should be adjusted separately for adequate diurnal rhythm of water turnover. About 1/3 of patients can be controlled by a single daily dose.

2. Nocturnal Enuresis (Bedwetting)

Fluid restriction is mandatory after the evening dose - restrict fluids 1 hour before and 8 hours after administration to prevent hyponatremia/water intoxication. Note: Many guidelines now prefer oral desmopressin (0.2-0.4 mg tablet or melt) over nasal spray for nocturnal enuresis due to more predictable absorption.

3. Hemophilia A / von Willebrand Disease (High-Strength Spray - 1.5 mg/mL)

• Tintinalli's Emergency Medicine; Campbell Walsh Wein Urology

Key Prescribing Notes

• Fluid restriction is mandatory in all age groups to avoid dilutional hyponatremia and water intoxication - this is especially dangerous in young children and elderly
• The nasal spray pump delivers only multiples of 10 mcg (0.1 mL); for doses < 10 mcg, a calibrated rhinal tube must be used
• Efficacy may be reduced by nasal congestion - consider switching to oral/parenteral route if congested
• Re-prime the pump if not used for > 1 week
• Storage: Refrigerate at 2-8°C; stable at room temperature (≤ 22°C) for up to 3 weeks during travel

Brands Available in India

Note: The high-strength Octim/Octostim nasal spray (1.5 mg/mL) used for hemophilia was subject to a global voluntary recall by Ferring Pharmaceuticals (initiated 2020, announced March 2025) due to packaging tightness issues. Confirm current availability with your supplier before prescribing for coagulation indications.

Summary Table

Desmopressin Nasal Spray - Indications, Age Groups, Doses & Indian Brands

Formulation

• Concentration: 0.01% w/v (0.1 mg/mL = 10 mcg per 0.1 mL spray)
• Delivery: Each pump actuation = 10 mcg
• Pack size: 5 mL bottle = 50 sprays
• Nasal bioavailability: 3-4% (intranasal is ~10-40x more potent than oral tablets)

Indications & Dosing by Age Group

1. Central (Cranial) Diabetes Insipidus

Morning and evening doses adjusted separately for adequate diurnal rhythm. ~1/3 of patients can be managed with a single daily dose.

2. Nocturnal Enuresis (Bedwetting)

Mandatory: Restrict fluids 1 hour before and 8 hours after the bedtime dose to prevent hyponatremia/water intoxication. Many current guidelines prefer oral desmopressin (tablet/melt) over nasal spray for enuresis due to more predictable absorption.

3. Hemophilia A / von Willebrand Disease Type I

Key Prescribing Points

• Pump delivers only multiples of 10 mcg - for doses < 10 mcg, use a calibrated rhinal tube
• Reduced efficacy during nasal congestion - switch to oral/SC route when congested
• Storage: Refrigerate 2-8°C; stable at room temperature (≤ 22°C) for up to 3 weeks while travelling
• Re-prime pump if unused for > 1 week
• Chief risk: dilutional hyponatremia and water intoxication - especially dangerous in young children and the elderly

Brands Available in India

Important note on high-strength spray (Octim/Octostim 1.5 mg/mL): Ferring Pharmaceuticals issued a global voluntary recall of this product in 2025 due to a packaging tightness issue. Verify current availability before prescribing for hemophilia/vWD indications.

Quick Reference Summary